Advertisement
BD Biosciences
BD Biosciences

Marburg Drug Shows Promise

Monkeys infected with lethal doses of Marburg virus were rescued by an experimental siRNA-based therapeutic, a study shows.

By | August 22, 2014

FLICKR, AJCANNAn experimental drug rescued monkeys infected with lethal doses of a virus closely related to Ebola even when given days after the infection occurred, according to research published this week (August 22) in Science Translational Medicine.

Like Ebola, Marburg virus infections also cause a deadly hemorrhagic fever that is fatal in 90 percent of affected individuals. Canadian company Tekmira Pharmaceuticals’ experimental medicine, TKM-Marburg, uses short interfering RNAs (siRNAs) encapsulated in nanoparticles, which block viral genes to treat infections. Earlier this month, the firm’s experimental drug TKM-Ebola was green-lighted by the US Food and Drug Administration for potential use to treat people with Ebola virus disease.

Researchers led by Thomas Geisbert of the University of Texas in Galveston and his colleagues from Tekmira infected 21 rhesus monkeys with potentially lethal doses of a virulent strain of Marburg. Groups of the monkeys were given the siRNA drug at different times after infection, ranging from 30 minutes to three days. All animals that received the drug survived, while control subjects died seven to nine days after treatment.

“This clearly starts to move into the realm of being a therapy, rather than a post-exposure treatment,” virologist Gene Olinger of MRIGlobal in Kansas City, Missouri, told Nature. “It’s a tougher point to intervene, so it’s important that they’ve demonstrated this.”

TKM-Ebola, uses a similar RNAi-based mechanism and is the only experimental drug to have reached clinical trials so far. Since TKM-Marburg worked several days after the animals were infected, it had “real-world utility,” Geisbert told The Washington Post. “This approach has the potential for use against all filoviruses [such as Marburg and Ebola].”

But not everyone is as convinced. Infectious diseases researcher Daniel Bausch of Tulane University told The New York Times that most people do not seek treatment for infections until symptoms began to appear, and in this study, none of the monkeys began to show symptoms until day six.

Nevertheless, the work “shows that you have a window of opportunity when you can actually intervene before the tipping point when people are going to be too ill to recover,” infectious diseases physician Amesh Adalja of the University of Pittsburgh told Nature.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo
Advertisement
Lonza
Lonza

Popular Now

  1. The Mycobiome
    Features The Mycobiome

    The largely overlooked resident fungal community plays a critical role in human health and disease.

  2. Antibody Alternatives
    Features Antibody Alternatives

    Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

  3. Circadian Clock and Aging
    Daily News Circadian Clock and Aging

    Whether a critical circadian clock gene is deleted before or after birth impacts the observed aging-related effects in mice.

  4. Holding Their Ground
    Features Holding Their Ground

    To protect the global food supply, scientists want to understand—and enhance—plants’ natural resistance to pathogens.

Advertisement
INTEGRA
INTEGRA
Advertisement
Life Technologies